Occupational and non-occupational attributable risk of asbestos exposure for malignant pleural mesothelioma

Conclusions Our study suggests that the overall ARp in women is largely driven by non-occupational asbestos exposure arguing for the strong impact of such exposure in pleural mesothelioma occurrence. Considering the difficulty in assessing domestic or environmental asbestos exposure, this could explain the observed difference in ARp between men and women.
Source: Thorax - Category: Respiratory Medicine Authors: Tags: Epidemiologic studies, Editor's choice, Respiratory cancer, Occupational and environmental medicine, Environmental issues Environmental exposure Source Type: research

Related Links:

Cellular Analytics, a biotechnology company in Ontario, Canada, has unveiled a novel liquid biopsy test for mesothelioma that could lead to more effective management of this rare cancer. The test has the potential to produce a much-earlier diagnosis of disease and the ability to personalize treatment and better predict a patient’s response to specific therapies. “We could change completely how this disease is viewed,” Dr. Brent Zanke, a specialist in diagnostic oncology and chief executive officer of Cellular Analytics, told The Mesothelioma Center at Asbestos.com. “It’s a proactive way to get...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Advanced Solid Tumors;   MSI-H/dMMR Tumors;   Cutaneous Squamous Cell Carcinoma;   Urothelial Carcinoma, HCC;   Cervical Cancer;   Esophageal Squamous Cell Carcinoma;   Merkel Cell Carcinoma, Small-cell Lung Cancer;   Mesothelioma;   PD-L1 Amplified Tumor (9p24.1);   Nasopharyngeal Carcinoma;   Cyclin-dependent Kinase 12 Mutated Tumors;   Basal Cell Carcinoma (Unresectable or Metastatic);   Sarcoma...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Malignant pleural mesothelioma (MPM) is highly aggressive neoplasm, with a median survival of
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Rodent models of malignant mesothelioma help facilitate the understanding of the biology of this highly lethal cancer and to develop and test new interventions. Introducing the same genetic lesions as found in human mesothelioma in mice results in tumors that show close resemblance with the human disease counterpart. This includes the extensive inflammatory responses that characterize human malignant mesothelioma. The relatively fast development of mesothelioma in mice when the appropriate combination of lesions is introduced, with or without exposure to asbestos, make the autochthonous models particularly useful for testi...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: The pPCI strongly differs from the sPCI for patients undergoing CRS for peritoneal disease and may provide a more accurate evaluation of the peritoneal disease extent. Further studies are needed to determine its prognostic value compared with sPCI, and consensus guidelines are needed for calculating it. PMID: 32040698 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
ml;ksel Godderis Malignant pleural mesothelioma (MPM) is mainly related to previous asbestos exposure. There is still dearth of information on non-invasive biomarkers to detect MPM at early stages. Human studies on exhaled breath biomarkers of cancer and asbestos-related diseases show encouraging results. The aim of this systematic review was to provide an overview on the current knowledge about exhaled breath analysis in MPM diagnosis. A systematic review was conducted on MEDLINE (PubMed), EMBASE and Web of Science databases to identify relevant studies. Quality assessment was done by the Newcastle–Ottawa...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Review Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Environmental Health | Epidemiology | Mesothelioma | Occupational Health | Respiratory Medicine | Study | Women